Biocon Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Civica, Inc. (Civica), a not-for-profit generic drug and pharmaceutical company founded in 2018 to address and resolve life-saving drug shortages and affordability

Insulin aspart is a fast-acting insulin injection used in the treatment of diabetes.

Under the terms of the agreement, Biocon Biologics will supply Insulin Aspart drug substance to Civica, Inc., who will use the drug substance to produce Insulin Aspart drug product, a rapid-acting insulin analog, at its manufacturing facility in Petersburg, Virginia. Civica will commercialize the medicine for patients in the United States, after completion of development work and clinical trials. No technology transfer is involved in the agreement.

This collaboration is in addition to the biocon biologics’ own Insulin Aspart Drug Product for the United States which is currently under U.S. Food and Drug Administration (FDA) review.

Shreehas Tambe, CEO & managing director, Biocon Biologics, said, “As a fully integrated global biologics company, Biocon Biologics is uniquely positioned to drive commercial success through tailored go-to-market strategies that create lasting value for all stakeholders. Our collaboration with Civica reflects this commitment, enabling us to expand patient access to Insulin Aspart in the United States while reinforcing our dedication to serving the growing needs of people living with diabetes. Together, we are working to ensure more patients have access to high-quality, affordable insulin.”

Ned McCoy, President and Chief Executive Officer, Civica, Inc., said, “Civica’s mission is to help people who need access to necessary generic and biosimilar medicines at affordable prices. This includes people living with diabetes, one in five of whom have skipped, delayed, or used less insulin than was needed to save money. Our partnership with Biocon Biologics for Aspart drug substance supply will allow us to deliver on our important mission and help people who need access to Insulin Aspart. Civica will utilize our U.S.-based manufacturing operations in Petersburg, Virginia to produce prefilled pens and vials of insulin.”

Biocon is an innovation-led global biopharmaceuticals company engaged in the production of therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small-molecule APIs in India and several key global markets, as well as generic formulations in the US, Europe, & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development.

The company had reported a consolidated net profit of Rs 25 crore in Q3 FY25, which is significantly lower as compared with the PAT of Rs 660 crore posted in Q3 FY24. Revenue from operations fell by 3% YoY to Rs 3,821 crore during the period under review.

The scrip rose 0.69% to Rs 335.40 on the BSE.

Powered by Capital Market - Live News

Biocon Ltd rose for a fifth straight session today. The stock is quoting at Rs 335.4, up 0.72% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.14% on the day, quoting at 22577. The Sensex is at 74336.54, down 0%. Biocon Ltd has dropped around 11.07% in last one month.

Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has dropped around 5.72% in last one month and is currently quoting at 20423.35, up 0.02% on the day. The volume in the stock stood at 26.6 lakh shares today, compared to the daily average of 34.76 lakh shares in last one month.

The benchmark March futures contract for the stock is quoting at Rs 335.2, up 0.48% on the day. Biocon Ltd is up 20.13% in last one year as compared to a 1.09% gain in NIFTY and a 6.38% gain in the Nifty Pharma index.

The PE of the stock is 0 based on TTM earnings ending December 24.

Powered by Capital Market - Live News

Biocon Ltd is up for a third straight session today. The stock is quoting at Rs 320.8, up 1.91% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.3% on the day, quoting at 22369.85. The Sensex is at 73855.47, up 1.19%. Biocon Ltd has slipped around 19.18% in last one month.

Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has slipped around 9.06% in last one month and is currently quoting at 19820.65, up 0.98% on the day. The volume in the stock stood at 24.03 lakh shares today, compared to the daily average of 35.14 lakh shares in last one month.

The benchmark March futures contract for the stock is quoting at Rs 321.75, up 1.98% on the day. Biocon Ltd is up 16.87% in last one year as compared to a 0.46% slide in NIFTY and a 4.57% slide in the Nifty Pharma index.

The PE of the stock is 0 based on TTM earnings ending December 24.

Powered by Capital Market - Live News

Biocon Ltd rose for a fifth straight session today. The stock is quoting at Rs 335.4, up 0.72% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.14% on the day, quoting at 22577. The Sensex is at 74336.54, down 0%. Biocon Ltd has dropped around 11.07% in last one month.

Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has dropped around 5.72% in last one month and is currently quoting at 20423.35, up 0.02% on the day. The volume in the stock stood at 26.6 lakh shares today, compared to the daily average of 34.76 lakh shares in last one month.

The benchmark March futures contract for the stock is quoting at Rs 335.2, up 0.48% on the day. Biocon Ltd is up 20.13% in last one year as compared to a 1.09% gain in NIFTY and a 6.38% gain in the Nifty Pharma index.

The PE of the stock is 0 based on TTM earnings ending December 24.

Powered by Capital Market - Live News

Biocon Ltd is up for a third straight session today. The stock is quoting at Rs 320.8, up 1.91% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.3% on the day, quoting at 22369.85. The Sensex is at 73855.47, up 1.19%. Biocon Ltd has slipped around 19.18% in last one month.

Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has slipped around 9.06% in last one month and is currently quoting at 19820.65, up 0.98% on the day. The volume in the stock stood at 24.03 lakh shares today, compared to the daily average of 35.14 lakh shares in last one month.

The benchmark March futures contract for the stock is quoting at Rs 321.75, up 1.98% on the day. Biocon Ltd is up 16.87% in last one year as compared to a 0.46% slide in NIFTY and a 4.57% slide in the Nifty Pharma index.

The PE of the stock is 0 based on TTM earnings ending December 24.

Powered by Capital Market - Live News

Lenalidomide is a medication used to treat types of multiple myeloma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, and anemia in myelodysplastic syndromes (MDS) in adults.

Dasatinib is used to treat Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in adults and children of 1 year of age and older. It is also used to treat Ph+CML and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) in adults after other medicines (eg, imatinib) or treatments did not work well. Dasatinib is also used in combination with chemotherapy to treat newly diagnosed Ph+ALL in children 1 year of age and older.

Additionally, Biocon Pharma has received tentative approval for its ANDA for Rivaroxaban Tablets USP, which is used to prevent blood clots and reduce the risk of stroke.

These approvals further add to Biocon’s portfolio of vertically integrated, complex drug products, the company said in a statement.

Biocon is an innovation-led global biopharmaceuticals company engaged in the production of therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small-molecule APIs in India and several key global markets, as well as generic formulations in the US, Europe, & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development.

The company had reported a consolidated net profit of Rs 25 crore in Q3 FY25, which is significantly lower as compared with the PAT of Rs 660 crore posted in Q3 FY24. Revenue from operations fell by 3% YoY to Rs 3,821 crore during the period under review.

Powered by Capital Market - Live News

Civica, Inc. (Civica), a not-for-profit generic drug and pharmaceutical company founded in 2018 to address and resolve life-saving drug shortages and affordability

Insulin aspart is a fast-acting insulin injection used in the treatment of diabetes.

Under the terms of the agreement, Biocon Biologics will supply Insulin Aspart drug substance to Civica, Inc., who will use the drug substance to produce Insulin Aspart drug product, a rapid-acting insulin analog, at its manufacturing facility in Petersburg, Virginia. Civica will commercialize the medicine for patients in the United States, after completion of development work and clinical trials. No technology transfer is involved in the agreement.

This collaboration is in addition to the biocon biologics’ own Insulin Aspart Drug Product for the United States which is currently under U.S. Food and Drug Administration (FDA) review.

Shreehas Tambe, CEO & managing director, Biocon Biologics, said, “As a fully integrated global biologics company, Biocon Biologics is uniquely positioned to drive commercial success through tailored go-to-market strategies that create lasting value for all stakeholders. Our collaboration with Civica reflects this commitment, enabling us to expand patient access to Insulin Aspart in the United States while reinforcing our dedication to serving the growing needs of people living with diabetes. Together, we are working to ensure more patients have access to high-quality, affordable insulin.”

Ned McCoy, President and Chief Executive Officer, Civica, Inc., said, “Civica’s mission is to help people who need access to necessary generic and biosimilar medicines at affordable prices. This includes people living with diabetes, one in five of whom have skipped, delayed, or used less insulin than was needed to save money. Our partnership with Biocon Biologics for Aspart drug substance supply will allow us to deliver on our important mission and help people who need access to Insulin Aspart. Civica will utilize our U.S.-based manufacturing operations in Petersburg, Virginia to produce prefilled pens and vials of insulin.”

Biocon is an innovation-led global biopharmaceuticals company engaged in the production of therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small-molecule APIs in India and several key global markets, as well as generic formulations in the US, Europe, & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development.

The company had reported a consolidated net profit of Rs 25 crore in Q3 FY25, which is significantly lower as compared with the PAT of Rs 660 crore posted in Q3 FY24. Revenue from operations fell by 3% YoY to Rs 3,821 crore during the period under review.

The scrip rose 0.69% to Rs 335.40 on the BSE.

Powered by Capital Market - Live News

Biocon Ltd rose for a fifth straight session today. The stock is quoting at Rs 335.4, up 0.72% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.14% on the day, quoting at 22577. The Sensex is at 74336.54, down 0%. Biocon Ltd has dropped around 11.07% in last one month.

Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has dropped around 5.72% in last one month and is currently quoting at 20423.35, up 0.02% on the day. The volume in the stock stood at 26.6 lakh shares today, compared to the daily average of 34.76 lakh shares in last one month.

The benchmark March futures contract for the stock is quoting at Rs 335.2, up 0.48% on the day. Biocon Ltd is up 20.13% in last one year as compared to a 1.09% gain in NIFTY and a 6.38% gain in the Nifty Pharma index.

The PE of the stock is 0 based on TTM earnings ending December 24.

Powered by Capital Market - Live News

Biocon Ltd is up for a third straight session today. The stock is quoting at Rs 320.8, up 1.91% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.3% on the day, quoting at 22369.85. The Sensex is at 73855.47, up 1.19%. Biocon Ltd has slipped around 19.18% in last one month.

Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has slipped around 9.06% in last one month and is currently quoting at 19820.65, up 0.98% on the day. The volume in the stock stood at 24.03 lakh shares today, compared to the daily average of 35.14 lakh shares in last one month.

The benchmark March futures contract for the stock is quoting at Rs 321.75, up 1.98% on the day. Biocon Ltd is up 16.87% in last one year as compared to a 0.46% slide in NIFTY and a 4.57% slide in the Nifty Pharma index.

The PE of the stock is 0 based on TTM earnings ending December 24.

Powered by Capital Market - Live News

Biocon Ltd rose for a fifth straight session today. The stock is quoting at Rs 335.4, up 0.72% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.14% on the day, quoting at 22577. The Sensex is at 74336.54, down 0%. Biocon Ltd has dropped around 11.07% in last one month.

Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has dropped around 5.72% in last one month and is currently quoting at 20423.35, up 0.02% on the day. The volume in the stock stood at 26.6 lakh shares today, compared to the daily average of 34.76 lakh shares in last one month.

The benchmark March futures contract for the stock is quoting at Rs 335.2, up 0.48% on the day. Biocon Ltd is up 20.13% in last one year as compared to a 1.09% gain in NIFTY and a 6.38% gain in the Nifty Pharma index.

The PE of the stock is 0 based on TTM earnings ending December 24.

Powered by Capital Market - Live News

Biocon Ltd is up for a third straight session today. The stock is quoting at Rs 320.8, up 1.91% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.3% on the day, quoting at 22369.85. The Sensex is at 73855.47, up 1.19%. Biocon Ltd has slipped around 19.18% in last one month.

Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has slipped around 9.06% in last one month and is currently quoting at 19820.65, up 0.98% on the day. The volume in the stock stood at 24.03 lakh shares today, compared to the daily average of 35.14 lakh shares in last one month.

The benchmark March futures contract for the stock is quoting at Rs 321.75, up 1.98% on the day. Biocon Ltd is up 16.87% in last one year as compared to a 0.46% slide in NIFTY and a 4.57% slide in the Nifty Pharma index.

The PE of the stock is 0 based on TTM earnings ending December 24.

Powered by Capital Market - Live News

Lenalidomide is a medication used to treat types of multiple myeloma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, and anemia in myelodysplastic syndromes (MDS) in adults.

Dasatinib is used to treat Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in adults and children of 1 year of age and older. It is also used to treat Ph+CML and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) in adults after other medicines (eg, imatinib) or treatments did not work well. Dasatinib is also used in combination with chemotherapy to treat newly diagnosed Ph+ALL in children 1 year of age and older.

Additionally, Biocon Pharma has received tentative approval for its ANDA for Rivaroxaban Tablets USP, which is used to prevent blood clots and reduce the risk of stroke.

These approvals further add to Biocon’s portfolio of vertically integrated, complex drug products, the company said in a statement.

Biocon is an innovation-led global biopharmaceuticals company engaged in the production of therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small-molecule APIs in India and several key global markets, as well as generic formulations in the US, Europe, & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development.

The company had reported a consolidated net profit of Rs 25 crore in Q3 FY25, which is significantly lower as compared with the PAT of Rs 660 crore posted in Q3 FY24. Revenue from operations fell by 3% YoY to Rs 3,821 crore during the period under review.

Powered by Capital Market - Live News